GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (FRA:NG2) » Definitions » EV-to-Revenue

Neogen (FRA:NG2) EV-to-Revenue : 4.73 (As of Nov. 10, 2024)


View and export this data going back to 1989. Start your Free Trial

What is Neogen EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Neogen's enterprise value is €3,972.7 Mil. Neogen's Revenue for the trailing twelve months (TTM) ended in Aug. 2024 was €840.1 Mil. Therefore, Neogen's EV-to-Revenue for today is 4.73.

The historical rank and industry rank for Neogen's EV-to-Revenue or its related term are showing as below:

FRA:NG2' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.58   Med: 6.79   Max: 12.07
Current: 4.7

During the past 13 years, the highest EV-to-Revenue of Neogen was 12.07. The lowest was 1.58. And the median was 6.79.

FRA:NG2's EV-to-Revenue is ranked worse than
62.5% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.175 vs FRA:NG2: 4.70

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-11-10), Neogen's stock price is €14.40. Neogen's Revenue per Share for the trailing twelve months (TTM) ended in Aug. 2024 was €3.88. Therefore, Neogen's PS Ratio for today is 3.71.


Neogen EV-to-Revenue Historical Data

The historical data trend for Neogen's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neogen EV-to-Revenue Chart

Neogen Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.20 9.77 4.69 5.38 3.86

Neogen Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.15 4.72 4.78 3.86 4.94

Competitive Comparison of Neogen's EV-to-Revenue

For the Diagnostics & Research subindustry, Neogen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neogen's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neogen's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Neogen's EV-to-Revenue falls into.



Neogen EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Neogen's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3972.685/840.106
=4.73

Neogen's current Enterprise Value is €3,972.7 Mil.
Neogen's Revenue for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €840.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neogen  (FRA:NG2) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Neogen's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=14.40/3.878
=3.71

Neogen's share price for today is €14.40.
Neogen's Revenue per Share for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.88.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neogen EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Neogen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Neogen Business Description

Traded in Other Exchanges
Address
620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.

Neogen Headlines

No Headlines